Trial Profile
Comparison of dobutamine, levosimendan, and dobutamine + levosimendan for the treatment of end-stage heart failure.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Sep 2012
Price :
$35
*
At a glance
- Drugs Dobutamine (Primary) ; Levosimendan (Primary)
- Indications Heart failure
- Focus Therapeutic Use
- 06 Sep 2012 Results published in the International Journal of Cardiology.
- 05 Nov 2010 New trial record.